Leriglitazone Reduces Cerebral Lesions and Improves Biomarkers Related to Axonal Degeneration, Inflammation and Compromised Blood-Brain-Barrier in Patients with Adrenomyeloneuropathy Mochel, F., Eichler, F., Engelen, M., Lachman, R., Fatemi, A., Sampson, J., Salsano, E., Gamez, J., Judith Molnar, M., Vilalta, A., Rodriguez-Pascau, L., Pizcueta, P., Pascual, S., Vila, A., Rovira, M., Pina, G., Mantilla, A., Pascual, M., Martinell, M., Meya, U., Kohler, W. WILEY. 2021: S129

View details for Web of Science ID 000704705300260